$KLDO News

Last published 4y ago

4y agoDAL KLDO NILE PCG+1Thinking about buying stock in Kaleido Biosciences, Royalty Pharma, PG&E Corp, Bitnile, or Delta Air Lines?PR NewswireNEW YORK, April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KLDO, RPRX, PCG, NILE, and DAL. T
4y agoAAL ATRS CLSN CTIC+1Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC.
4y agoKLDO RDUSRadius Health Announces Leadership AppointmentsGlobeNewswireBOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Compa
4y agoAXLA CDAK DNLI EVLO+8Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsPR NewswireCAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pa
4y agoAXLA CDAK DNLI EVLO+7INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTPR NewswireCAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental chall
4y agoAXLA CDAK DNLI EVLO+8Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New MedicinesBusiness WireCompany increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity,
4y agoAXLA CDAK DNLI EVLO+8Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyPR NewswireCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President
4y agoAXLA CDAK DNLI EVLO+8Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental StrategyPR NewswireCAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental St
4y agoKLDOKaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis CongressGlobeNewswireLEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the r
4y agoAXLA CDAK DNLI EVLO+9Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of DirectorsBusiness WireEstepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity
4y agoKLDOKaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic ConditionsGlobeNewswireLEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the r
4y agoAXLA CDAK DNLI EVLO+8Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation PlatformBusiness Wire- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly sc
4y agoAXLA CDAK DNLI EVLO+8Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate DevelopmentPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this
4y agoKLDOKaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireLEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the r
5y agoKLDOKaleido Biosciences to Appoint Dr. Alison Long as Chief Medical OfficerGlobeNewswireLEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the r
5y agoAXLA CDAK DNLI EVLO+8Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic FibrosisBusiness WireTessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundatio
5y agoKLDOKaleido Biosciences Reports Third Quarter 2021 Financial ResultsGlobeNewswire--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on trac
5y agoAXLA CDAK DNLI EVLO+7Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangePR NewswireCAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into
5y agoKLDOKaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics SummitGlobeNewswireLEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the r
5y agoKLDOKaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative ColitisGlobeNewswireKB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at
5y agoKLDOKaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021GlobeNewswireLatest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 stud
5y agoKLDOCoronavirus (COVID-19) Update: September 7, 2021FDA Press ReleasesThe U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participating in clinical trials, during ...
5y agoKLDOKaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare ConferenceGlobeNewswireLEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, to
5y agoKLDOKaleido Biosciences Reports Second Quarter 2021 Financial ResultsGlobeNewswire--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to
5y agoKLDOKaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical TrialGlobeNewswireLEXINGTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, tod
5y agoKLDOKaleido Biosciences Announces New Chairperson Appointment to its Board of DirectorsGlobeNewswireLEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, tod
5y agoKLDOKaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth ConferenceGlobeNewswireLEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, tod
5y agoAXLA CDAK DNLI EVLO+7Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of DirectorsBusiness WireNew Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. an
5y agoAXLA CDAK DNLI EVLO+7Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and SustainabilityPR NewswireCAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability c
5y agoKLDOKaleido Biosciences to Participate in the JMP Securities Life Sciences ConferenceGlobeNewswireLEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, tod
5y agoAXLA CDAK DNLI EVLO+7Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological AgriculturePR NewswireCAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges,
5y agoAXLA CDAK DNLI EVLO+7Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus GreeningPR NewswireCAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, a
5y agoKLDOKaleido Biosciences Reports First Quarter 2021 Financial ResultsGlobeNewswire--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 i
5y agoKLDOKaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile NeutropeniaGlobeNewswireLEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announc
5y agoKLDOKaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics SummitGlobeNewswireLEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
5y agoAXLA CDAK DNLI EVLO+7Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic DevelopmentBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations. The senior appointments come just two months after the compan ...
5y agoAXLA CDAK DNLI EVLO+7Flagship Pioneering Expands Leadership Team with Appointment of Michael T. Nally as CEO-PartnerPR NewswireFlagship Pioneering today announced the expansion of its senior leadership team with the appointment of Michael T. Nally as CEO-Partner. In this...
5y agoAXLA CDAK DNLI EVLO+7Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial OfficerPR NewswireInvaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve...
5y agoKLDOAn Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120 - NCT04814914ClinicalTrials.govProportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.
5y agoKLDOKaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More ComorbidityGlobeNewswireKB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal...
5y agoKLDOKaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewswireTopline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021 LEXINGTON,...
5y agoKLDOKaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines SummitGlobeNewswireLEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
5y agoAXLA CDAK DNLI EVLO+7Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular TargetPR NewswireCellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that...
5y agoKLDOKaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common StockGlobeNewswireLEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
5y agoKLDOKaleido Biosciences Announces Pricing of Public Offering of Common StockGlobeNewswireLEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
5y agoKLDOKaleido Biosciences Announces Proposed Public Offering of Common StockGlobeNewswireLEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
5y agoKLDOKaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” ConferenceGlobeNewswireLEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone...
5y agoKLDOKaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19GlobeNewswirePreliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from...
5y agoAXLA DNLI EVLO FHTX+5Flagship Pioneering Unveils Inzen TherapeuticsPR NewswireFlagship Pioneering, a life science platforms company, today announced the unveiling of Inzen Therapeutics. Flagship created Inzen in 2017 to...
5y agoAXLA DNLI EVLO FHTX+5Flagship Pioneering Unveils Pioneering MedicinesPR NewswireFlagship Pioneering, a life science platforms company, today unveiled Pioneering Medicines, a new division of Flagship Pioneering. Initiated in 2020, ...